Streetbeat News

Regulatory

ZVSA

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) has announced the publication of an article in the peer-reviewed journal Circulation. The article demonstrates the role of inflammasome NLRP3 activation in hypertrophic heart disease induced by mechanical stress. ZyVersa is a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:42 am

FXI

China's Central Bank has extended policies to support the stable and healthy development of real estate markets until the end of 2024. This encourages financial institutions and real estate enterprises to negotiate independently.

Portfolio Pulse from Charles Gross

July 10, 2023 | 11:36 am

IOVA

Iovance Biotherapeutics has announced regulatory and clinical updates for its polyclonal tumor infiltrating lymphocyte therapy in advanced non-small cell lung cancer. The updates could potentially impact the company's future prospects and stock performance.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:19 am

NVS

The US Food and Drug Administration (FDA) has approved a label update for Novartis' Leqvio (inclisiran) to enable its use in patients with elevated LDL-C who have an increased risk of heart disease. This includes patients with comorbidities such as hypertension and diabetes who have not yet had a first cardiovascular event.

Portfolio Pulse from Charles Gross

July 10, 2023 | 11:16 am

IOVA

Iovance Biotherapeutics has announced regulatory and clinical updates for its TIL therapy in advanced non-small cell lung cancer. The updates could potentially impact the company's future operations and stock performance.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:10 am

CLSD

Clearside Biomedical's new drug application for Arcatus (ARVN001) for Uveitic Macular Edema has been accepted by the Therapeutic Goods Administration of Australia. Arctic Vision, a China-based ophthalmology company, holds the exclusive license for the commercialization and development of Arcatus in several countries including Australia.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:09 am

MRKR

Marker Therapeutics announced that its product candidate, MT-401, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the treatment of patients with acute myeloid leukemia (AML).

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:08 am

TNXP

Tonix Pharmaceuticals has enrolled the first participant in its Phase 2 'POWER' study of TNX-1900, a treatment for pediatric obesity, at the Massachusetts General Hospital.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:06 am

EXAI

Exscientia plc (NASDAQ:EXAI) has enrolled the first patient in its Phase 1/2 'ELUCIDATE' study evaluating GTAEXS617, a CDK7 inhibitor, for the treatment of advanced solid tumours. The trial will assess the safety, efficacy and pharmacokinetics of '617 across multiple ascending doses in patients with various types of cancer. '617 was designed by Exscientia in collaboration with GT Apeiron.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:03 am

KRMD

KORU Medical has submitted a 510(K) application for its Freedom60 Infusion System with Hizentra 50 ml prefilled syringes. The submission is currently under review by the FDA.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:03 am